Following on from information provided to NICE by the company in May 2019, the appraisal of Lung cancer (non-small-cell, untreated, high tumour mutational burden) - ipilimumab (with nivolumab) was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 1187 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
| External Assessment Group | Kleijnen Systematic Reviews |
Stakeholders
| Companies sponsors | Bristol-Myers Squibb (nivolumab, ipilimumab) |
| Others | Department of Health and Social Care |
| NHS England | |
| Welsh Government | |
| Patient carer groups | Roy Castle Lung Cancer Foundation |
| Professional groups | Association of Cancer Physicians |
| British Thoracic Oncology Group | |
| Cancer Research UK | |
| Royal College of Physicians | |
| Royal College of Radiologists | |
| Comparator companies | Accord Healthcare (carboplatin, cisplatin, docetaxel, gemcitabine, paclitaxel) (Confidentiality agreement not signed, not participating) |
| Allergan (docetaxel, gemcitabine, paclitaxel, pemetrexed, vinorelbine) (Confidentiality agreement not signed, not participating) | |
| Celgene (paclitaxel) (Confidentiality agreement not signed, not participating) | |
| Dr Reddy’s laboratories (docetaxel) (Confidentiality agreement not signed, not participating) | |
| Eli Lilly (gemcitabine, pemetrexed) (Confidentiality agreement not signed, not participating) | |
| Hospira UK (cisplatin, carboplatin, docetaxel, gemcitabine, paclitaxel) (Confidentiality agreement not signed, not participating) | |
| Medac GmbH (docetaxel, gemcitabine, paclitaxel, vinorelbine) (Confidentiality agreement not signed, not participating) | |
| Merck Sharp and Dohme (pembrolizumab) | |
| Pfizer (carboplatin, cisplatin, docetaxel, gemcitabine, paclitaxel) (Confidentiality agreement not signed, not participating) | |
| Pierre Fabre (vinorelbine) (Confidentiality agreement not signed, not participating) | |
| Sandoz (cisplatin) (Confidentiality agreement not signed, not participating) | |
| Sanofi (docetaxel) (Confidentiality agreement not signed, not participating) | |
| Seacross pharmaceuticals (docetaxel, paclitaxel, pemetrexed) (Confidentiality agreement not signed, not participating) | |
| Sun Pharmaceuticals (carboplatin, gemcitabine) (Confidentiality agreement not signed, not participating) | |
| Teva UK (docetaxel) (Confidentiality agreement not signed, not participating) | |
| General commentators | All Wales Therapeutic and Toxicology Centre |
| British National Formulary | |
| Department of Health, Social Services and Public Safety for Northern Ireland | |
| Healthcare Improvement Scotland | |
| Welsh Health Specialised Services Committee | |
| Relevant research groups | Genomics England |
| Institute of Cancer Research |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 16 November 2022 | Discontinued. Following on from information provided to NICE by the company in May 2019, the appraisal of Lung cancer (non-small-cell, untreated, high tumour mutational burden) - ipilimumab (with nivolumab) was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 31 March 2020 | The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of nivolumab with ipilimumab for untreated non-small-cell lung cancer that has a high tumour mutational burden [ID1187] For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the European Medicines Agency for this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes. |
| 08 November 2018 | Committee meeting: 1 |
| 29 October 2018 | Suspended. Suspended |
| 29 October 2018 | The company (Bristol-Myers Squibb) requested that NICE suspend this appraisal because of a change to its regulatory timelines for this indication. Therefore, the discussion of this topic at the appraisal committee meeting (previously scheduled for 8 November 2018) will be rescheduled. We will provide a further update and rescheduled timelines in due course. |
| 12 June 2018 | Invitation to participate |
| 01 May 2018 - 24 May 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
| 11 September 2017 - 09 October 2017 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
| 12 September 2017 | In progress. In progress |
For further information on our processes and methods, please see our CHTE processes and methods manual